Vimarsana
Biggest News Aggregation in the World

Page 4 - Fda Approval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Fda Approval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Fda Approval Today - Breaking & Trending Today

WOVEN ORTHOPEDICS SECURES SECOND FDA SPINE CLEARANCE - OGMEND® NOW AVAILABLE FOR MOST PEDICLE SCREW DIAMETERS - Vimarsana News

WOVEN ORTHOPEDICS SECURES SECOND FDA SPINE CLEARANCE - OGMEND® NOW AVAILABLE FOR MOST PEDICLE SCREW DIAMETERS

/PRNewswire/ -- Woven Orthopedic Technologies, developer of Ogmend®, a simple implantable sleeve that quickly and easily secures stable screw fixation, has...

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript - Vimarsana News

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript February 28, 2024 Iovance Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.45 EPS, expectations were $-0.44. Iovance Biotherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to […]

Source: yahoo.com
New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies - Vimarsana News

New England Journal of Medicine publishes Phase III data showing Xolair® (omalizumab) significantly reduced allergic reactions across multiple foods in people with food allergies

Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat...

Centinel Spine's lumbar disc replacement implant earns new payer coverage - Vimarsana News

Centinel Spine's lumbar disc replacement implant earns new payer coverage

Centinel Spine earned coverage from a large commercial payer in Tennessee for one- and two-level lumbar disc replacement, the devicemaker said Feb. 21.

It's A First; Cellular Therapy For Melanoma And Drug To Reduce Food Allergic Reactions Get FDA Nod - Vimarsana News

It's A First; Cellular Therapy For Melanoma And Drug To Reduce Food Allergic Reactions Get FDA Nod

Latest approvals by the U.S. Food and Drug Administration include Iovance Biotherapeutics Inc.'s Amtagvi - the first cellular therapy indicated for the treatment of unresectable or metastatic melanoma, as well as Genentech's Xolair- the first medication to help reduce allergic reactions to multiple foods after accidental exposure.